Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2002 6
2003 6
2004 9
2005 12
2006 30
2007 31
2008 57
2009 67
2010 69
2011 97
2012 132
2013 162
2014 192
2015 221
2016 245
2017 288
2018 354
2019 472
2020 551
2021 595
2022 729
2023 702
2024 872
2025 996
2026 414

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,490 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for meng li
Search for imeng li instead (1 results)
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale RP, Li W, Liu X, Zhu H, Pan L, Yang Y, Lin H, Du X, Liang R, Chen C, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Huang X, Jiang Q. Zhang X, et al. Among authors: meng l. Blood. 2024 Oct 31;144(18):1951-1961. doi: 10.1182/blood.2024024761. Blood. 2024. PMID: 39046786 Free PMC article.
Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.
Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, Gao S, Zhang N, Jing R, Sun J, Wang H, Hui E, Wong CC, Xu C. Wu W, et al. Among authors: meng l. Cell. 2020 Aug 20;182(4):855-871.e23. doi: 10.1016/j.cell.2020.07.018. Epub 2020 Jul 29. Cell. 2020. PMID: 32730808 Free article.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: meng l. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.
Zhang X, Yang Y, Liu B, Du X, Wang X, Zhu H, Yu L, Li Z, Zhao S, Yang L, Ma Y, Meng L, Zhang Y, Li G, Yang L, Wang B, Ran X, Huang J, Gao N, Wen Q, Wen Y, Zhao Y, Zhu Y, Han Y, Liu Z, Du X, Weng J, Gale RP, Zhou L, Zhang Y, Jiang Q. Zhang X, et al. Among authors: meng l. Haematologica. 2025 Dec 1;110(12):2986-2996. doi: 10.3324/haematol.2024.287116. Epub 2025 Apr 30. Haematologica. 2025. PMID: 40304058 Free PMC article.
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q. Yang S, et al. Among authors: meng l. Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2. Am J Hematol. 2023. PMID: 37128776 Free article. No abstract available.
6,490 results